JP2019519470A - Ｉｌ−６受容体へのｉｌ−６の結合を遮断する薬剤を用いたうつ病の治療 - Google Patents

Ｉｌ−６受容体へのｉｌ−６の結合を遮断する薬剤を用いたうつ病の治療 Download PDF

Info

Publication number
JP2019519470A
JP2019519470A JP2018552798A JP2018552798A JP2019519470A JP 2019519470 A JP2019519470 A JP 2019519470A JP 2018552798 A JP2018552798 A JP 2018552798A JP 2018552798 A JP2018552798 A JP 2018552798A JP 2019519470 A JP2019519470 A JP 2019519470A
Authority
JP
Japan
Prior art keywords
antibody
seq
antibodies
human
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018552798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519470A5 (enExample
Inventor
チェン，グアン
スン，ユ
ワン，ダイ
ウィッテンバーグ，ゲイル
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド, ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2019519470A publication Critical patent/JP2019519470A/ja
Publication of JP2019519470A5 publication Critical patent/JP2019519470A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018552798A 2016-04-07 2017-04-06 Ｉｌ−６受容体へのｉｌ−６の結合を遮断する薬剤を用いたうつ病の治療 Pending JP2019519470A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319558P 2016-04-07 2016-04-07
US62/319,558 2016-04-07
PCT/US2017/026395 WO2017177032A2 (en) 2016-04-07 2017-04-06 Treatment of depression using agents that block binding of il-6 to il-6 receptor

Publications (2)

Publication Number Publication Date
JP2019519470A true JP2019519470A (ja) 2019-07-11
JP2019519470A5 JP2019519470A5 (enExample) 2020-05-07

Family

ID=59998986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018552798A Pending JP2019519470A (ja) 2016-04-07 2017-04-06 Ｉｌ−６受容体へのｉｌ−６の結合を遮断する薬剤を用いたうつ病の治療

Country Status (7)

Country Link
US (1) US20170291942A1 (enExample)
EP (1) EP3440108A4 (enExample)
JP (1) JP2019519470A (enExample)
AU (1) AU2017248280A1 (enExample)
CA (1) CA3019828A1 (enExample)
MA (1) MA44631A (enExample)
WO (1) WO2017177032A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019215701A1 (en) * 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516158A (ja) * 2009-01-29 2012-07-19 メディミューン，エルエルシー 延長したインビボ半減期を有するヒト抗ｉｌ−６抗体ならびに腫瘍学、自己免疫疾患、および炎症性疾患の治療におけるそれらの使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004671A (es) * 2001-11-14 2005-08-25 Johnson & Johnson Anticuerpos anti-interleucina-6, composiciones, metodos y usos.
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
JP6347477B2 (ja) * 2013-12-27 2018-06-27 国立大学法人千葉大学 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516158A (ja) * 2009-01-29 2012-07-19 メディミューン，エルエルシー 延長したインビボ半減期を有するヒト抗ｉｌ−６抗体ならびに腫瘍学、自己免疫疾患、および炎症性疾患の治療におけるそれらの使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AM J PATHOL., vol. 165, no. 2, JPN6021013542, 2004, pages 471 - 480, ISSN: 0004656511 *
ANNALS OF THE RHEUMATIC DISEASES, vol. 74, no. 2, JPN6021013524, 2015, pages 0182 - 720, ISSN: 0004656507 *
EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. Vol. 25, Abstract No. P.2.b.033, JPN6021013530, 2015, pages 403 - 404, ISSN: 0004656509 *
EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. Vol. 25, Suppl. 2, JPN6021013527, 2015, pages 2 - 016, ISSN: 0004656508 *
NEUROPSYCHOPHARMACOLOGY, vol. Vol. 40, No. Suppl. 1, Abstract No. M117, JPN6021013518, 2015, pages 181 - 182, ISSN: 0004656506 *
PATIENT, vol. 8, no. 2, JPN6021013537, 2015, pages 207 - 216, ISSN: 0004656510 *

Also Published As

Publication number Publication date
US20170291942A1 (en) 2017-10-12
WO2017177032A3 (en) 2017-11-16
WO2017177032A2 (en) 2017-10-12
CA3019828A1 (en) 2017-10-12
AU2017248280A1 (en) 2018-10-25
EP3440108A2 (en) 2019-02-13
MA44631A (fr) 2019-02-13
EP3440108A4 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
JP5193881B2 (ja) ヒト抗ｉｌ−２３抗体、組成物、方法および用途
JP5940565B2 (ja) 抗−ｉｌ−６抗体、組成物、方法および使用
US8574579B2 (en) Anti-IL-23 antibodies
TWI406943B (zh) 抗-ｉｌ-１２抗體、抗原決定部位、組成物、方法及用途
JP2019514858A (ja) 抗ｉｌ１２及び／又は−２３抗体の増加した間隔投与による乾癬の処置
US20190345245A1 (en) Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
CN101351560A (zh) B细胞增殖剂用于产生抗体的用途
JP2019519470A (ja) Ｉｌ−６受容体へのｉｌ−６の結合を遮断する薬剤を用いたうつ病の治療
HK1124548B (en) Human anti-il-23 antibodies, compositions, methods and uses
BRPI0612728A2 (pt) anticorpos de anti-il-23p19, composições, métodos e usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211207

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220407

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220419

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220419

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20220607

C032 Notice prior to dismissal

Free format text: JAPANESE INTERMEDIATE CODE: C032

Effective date: 20220628

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220628